Drug intelligence / Profile preview

Yanli Capsule

Development stage: Unknown
Lead developer: Jiangxi Jiewang Pharmaceutical
Administration: Oral

Overview

Yanli Capsule (延力胶囊) is a Traditional Chinese Medicine (TCM) product developed by Jiangxi Jiewang Pharmaceutical for the treatment of functional erectile dysfunction, specifically in patients presenting with kidney yang deficiency syndrome. As a botanical combination therapy, it is formulated as an oral capsule. The drug has undergone clinical evaluation in China, including a Phase II trial (CTR20150212) intended to preliminarily assess its safety and efficacy in improving sexual function and alleviating symptoms associated with the depletion of kidney yang.

Brand names: Yanli Capsule
Other names: Yanli Jiaonang

Targets

PDE5 (Phosphodiesterase 5A)

Beyond the preview

Go deeper on Yanli Capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yanli Capsule.

Explore the full profile